Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JZP-361 is a specific MAGL inhibitor with IC50s of 46 nM, 7.24 μM, and 1.79 μM for human recombinant MAGL, human recombinant FAAH, and human hABHD6. JZP-361 displays anti-histaminergic activities. JZP-361 can be used in studies about asthma.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 15,000 | |||
10 mg | 在庫あり | ¥ 22,500 | |||
25 mg | 在庫あり | ¥ 45,500 | |||
50 mg | 在庫あり | ¥ 75,500 | |||
100 mg | 在庫あり | ¥ 113,500 | |||
500 mg | 在庫あり | ¥ 245,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 16,000 |
説明 | JZP-361 is a specific MAGL inhibitor with IC50s of 46 nM, 7.24 μM, and 1.79 μM for human recombinant MAGL, human recombinant FAAH, and human hABHD6. JZP-361 displays anti-histaminergic activities. JZP-361 can be used in studies about asthma. |
ターゲット&IC50 | FAAH (human):7.24 μM, ABHD6 (human):1.79 μM, MAGL (human):46 nM, H1 receptor:6.81 (pA2) |
In vitro | JZP-361 shows the affinity of H1 antagonistic with a pA2 of 6.81). JZP-361(≤10 μM) does not show cannabinoid receptor activity. JZP-361 displays favorable interactions within the important hydrogen-bonding of the carbonyl oxygen to the oxyanion hole[1]. |
別名 | JZP361, JZP 361 |
分子量 | 405.88 |
分子式 | C22H20ClN5O |
CAS No. | 1680193-80-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 36.5 mg/mL (90.0 mM)
DMSO: 7.3 mg/mL (18.0 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JZP-361 1680193-80-9 Metabolism Lipase JZP361 JZP 361 Inhibitor inhibitor inhibit